Clinical Advances in Breast Cancer
(Z)-endoxifen Demonstrated Encouraging Neoadjuvant Activity in Premenopausal Breast Cancer
April 19, 2024
Neoadjuvant (Z)-endoxifen demonstrated promising antitumor activity for premenopausal patients with ER-positive, HER2-negative breast cancer...
Addition of Atezolizumab to Carboplatin Extends Survival for TNBC
March 7, 2024The addition of atezolizumab to carboplatin chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (TNBC) regardless of PD-L1 status...
ASTRO Issues Recommendations for Partial Breast Irradiation in Early-Stage Breast Cancer, DCIS
January 1, 2024The American Society of Radiation Oncology (ASTRO) recently issued new guidelines for the appropriate use of partial breast irradiation (PBI) for patients receiving treatment for ductal carcinoma in situ (DCIS)...
Zotatifin-Based Triplet Effective in Metastatic Breast Cancer, Receives Fast Track Designation
January 1, 2024The combination of zotatifin plus fulvestrant and abemaciclib demonstrated promising activity in a cohort of heavily pretreated patients with ER-positive metastatic breast cancer...
Certain Younger Postmenopausal Women Can Safely Avoid Radiation After Breast-Conserving Surgery
January 1, 2024Certain younger postmenopausal patients with breast cancer can safely omit adjuvant radiotherapy after breast-conserving surgery and endocrine therapy without facing an increased risk of recurrence...
FDA Approves Capivasertib Plus Fulvestrant for Breast Cancer with AKT Pathway Alterations
January 1, 2024The FDA approved capivasertib, in combination with fulvestrant, for the treatment of patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer...
